TOWARD CONTROLLED-RELEASE DRUG DELIVERY MICROCARRIERS ENABLED BY DIRECT LASER WRITING 3D PRINTING.
TOWARD CONTROLLED-RELEASE DRUG DELIVERY MICROCARRIERS ENABLED BY DIRECT LASER WRITING 3D PRINTING.
复制标题
通过直接激光书写 3D 打印实现控释药物递送微载体。
DOI：
10.1109/mems58180.2024.10439600
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Sochol,RyanD
中科院分区：
文献类型：
--
作者：
Sarker,Sunandita;Forghani,Kimia;Wen,Ziteng;Halli,RyanN;Hoag,Stephen;Flank,Sharon;Sochol,RyanD
控释，尤其是长效的药物输送系统有望改善多种医疗状况的治疗。此前，我们报道了一种增材制造或“三维（3D）打印”方法，用于制造包含标准光致抗蚀剂的液体核壳帽微载体。在这里，我们探索了扩展这一策略的潜力，以实现包含可生物降解材料的微载体，作为控释药物递送选择的新途径。具体来说，我们研究了使用“双光子直接激光写入（DLW）”作为 3D 打印微载体的方法，微载体由以下组成：（i）带有孔口的瓶形“壳”，（ii）水性液体“核心”，以及（iii）可生物降解的“帽”。该盖子采用 DLW 技术直接打印在外壳的孔口上，旨在随着时间的推移在体内降解（例如，降解时间与盖子厚度成正比），以最终促进液体核心在所需时间点释放。基于使用可生物降解的聚乙二醇二丙烯酸酯 (PEGDA) 光材料进行盖帽的制造结果表明，结合微流体阻塞结构的外壳设计似乎限制了液相 PEGDA 意外进入外壳（即，直接在盖帽印刷之前），从而在盖帽印刷过程完成后改善了液体核心的保留。这些结果标志着评估所提出的 DLW 3D 打印策略在可能的药物输送应用中的效用迈出了重要的第一步。
Controlled-release, and especially long-acting, drug delivery systems hold promise for improving treatments for numerous medical conditions. Previously, we reported an additive manufacturing or "three-dimensional (3D) printing" approach for fabricating liquid-core-shell-cap microcarriers comprising standard photoresists. Here we explore the potential to extend this strategy to achieve microcarriers comprising biodegradable materials as a new pathway to controlled-release drug delivery options. Specifically, we investigate the use of "Two-Photon Direct Laser Writing (DLW)" as a means to 3D print microcarriers composed of: (i) a bottle-shaped "shell" with an orifice, (ii) an aqueous liquid "core", and (iii) a biodegradable "cap". The cap, which is DLW-printed directly onto the shell’s orifice, is designed to degrade over time in the body—e.g., with degradation time proportional to cap thickness—to ultimately facilitate release of the liquid core at desired time points. Fabrication results based on the use of a biodegradable poly(ethylene glycol) diacrylate (PEGDA) photomaterial for the cap revealed that shell designs incorporating microfluidic obstruction structures appeared to limit undesired entry of the liquidphase PEGDA into the shell (i.e., directly preceding cap printing), thereby resulting in improved retention of the liquid core after completion of the cap printing process. These results mark an important first step toward evaluating the utility of the presented DLW 3D printing strategy for possible drug delivery applications.